Table 2.
COVID-19-related ARDS patients’ characteristics at the time of blood sampling.
| Survivors | Non-survivors | p-value | |
|---|---|---|---|
| N = 25 | N = 25 | ||
| Age (years) | 60 [54–70] | 62 [52–69] | 0.99 |
| Sex (male) | 17 (68%) | 17 (68%) | 1.00 |
| Body mass index (kg/m²) | 28 [25–38] | 31 [27–36] | 0.65 |
| Hypertension | 13 (52%) | 18 (72%) | 0.48 |
| Diabetes mellitus | 5 (20%) | 11 (44%) | 0.15 |
| Chronic kidney disease | 0 (0%) | 0 (0%) | 1.00 |
| Chronic heart disease | 5 (20%) | 2 (8%) | 0.39 |
| Chronic obstructive pulmonary disease | 1 (4%) | 11 (44%) | <0.01 |
| Immunosuppressive drug before COVID-19 | 3 (12%) | 8 (32%) | 0.39 |
| SOFA | 4 [2–9] | 5 [2–8] | 0.99 |
| PaO2/FiO2 (mmHg) | 149 [115–275] | 160 [86–212] | 0.39 |
| Fibrinogen (g/L) | 7.6 [6.7–9] | 7.5 [5.1–8.5] | 0.39 |
| D-dimers (mg/L) | 1,342 [751–3,760] | 3,450 [1,930–8,850] | 0.05 |
| Platelets (/mm3) | 294,000 [178,000–393,000] | 166,000 [107,000–297,000] | 0.06 |
| Neutrophils (/mm3) | 5,240 [4,100–9,000] | 7,850 [4,430–13,980] | 0.26 |
| Lymphocytes (/mm3) | 840 [680–1,400] | 750 [325–1,025] | 0.12 |
| Albumin (g/L) | 23 [18–26.8] | 25 [18–28.5] | 0.64 |
| C-reactive protein (mg/L) | 137 [77–229] | 118 [69–267] | 0.88 |
| Invasive ventilation | 19 (83%) | 25 (100%) | 0.27 |
| ECMO | 1 (4%) | 8 (32%) | 0.005 |
| Corticosteroids | 8 (32%) | 10 (40%) | 0.72 |
| Immunomodulating agents | 4 (16%) | 4 (16%) | 1.00 |
| Antiviral agents | 8 (32%) | 9 (36%) | 1.00 |
Continuous variables are presented as median and interquartile range and are compared using Mann–Whitney test. Categorical variables are expressed as the number of patients (percentage) and are compared using Fisher’s exact test. ARDS, acute respiratory distress syndrome; ECMO, extracorporeal membrane oxygenation; MPO–DNA, myeloperoxidase–DNA; SOFA, sequential organ failure assessment score; %ST, % Standard NETs.